Monica Forbes
Corporate Officer/Principal en APOGEE THERAPEUTICS, INC. .
Fortuna: 41 464 $ al 30/04/2024
Origen de la red de primer grado Monica Forbes.
| Entidad | Tipo de entidad | Industria | |
|---|---|---|---|
| Subsidiary | Pharmaceuticals: Major | 24 | |
| Extinct | Pharmaceuticals: Major | 23 | |
| Public Company | Biotechnology | 19 | |
Nalpropion Pharmaceuticals, Inc.
 Nalpropion Pharmaceuticals, Inc. Managed Health CareHealth Services Nalpropion Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the treatment of weight loss. Its products include CONTRAVE, analtrexone HCl & bupropion HCl extended release and Mysimba, a naltrexone HCl/ bupropion HCl prolonged release. The company is headquartered in Morristown, NJ.
1
| Subsidiary | Managed Health Care | 1 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Monica Forbes a través de su red personal
| Empresa | Sector | Personas relacionadas | Puesto principal |
|---|---|---|---|
| Stanford University | College/University | Undergraduate Degree Graduate Degree Doctorate Degree Doctorate Degree | |
| The Trustees of Columbia University in The City of New York | College/University | Graduate Degree Graduate Degree Graduate Degree Graduate Degree | |
| SPYRE THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
| BRIDGEBIO PHARMA, INC. | Biotechnology | Corporate Officer/Principal Human Resources Officer Corporate Officer/Principal | |
| University of California, Irvine | College/University | Corporate Officer/Principal Masters Business Admin Doctorate Degree | |
| TREVENA, INC. | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal Corporate Officer/Principal | |
| University of California, Santa Barbara | College/University | Undergraduate Degree Graduate Degree Undergraduate Degree | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Sales & Marketing General Counsel Corporate Officer/Principal | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Sales & Marketing Sales & Marketing Director of Finance/CFO | |
| San Diego State University | College/University | Undergraduate Degree Undergraduate Degree | |
| EYEPOINT PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
| UCLA School of Law | College/University | Graduate Degree Graduate Degree | |
| ATARA BIOTHERAPEUTICS, INC. | Pharmaceuticals: Major | General Counsel Director/Board Member | |
| SANGAMO THERAPEUTICS, INC. | Biotechnology | General Counsel Investor Relations Contact | |
| SPECTRUM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO Comptroller/Controller/Auditor | |
| INVIVYD, INC. | Biotechnology | Chief Tech/Sci/R&D Officer Director of Finance/CFO | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Undergraduate Degree Undergraduate Degree | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
| EQUILLIUM, INC. | Biotechnology | Director/Board Member Director of Finance/CFO | |
| PHASEBIO PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal General Counsel | |
| REGULUS THERAPEUTICS INC. | Pharmaceuticals: Major | Chief Executive Officer President | |
Domain Associates LLC
 Domain Associates LLC Investment ManagersFinance Domain Associates LLC (Domain Associates) is a venture capital firm founded in 1985. The firm is headquartered in Princeton, New Jersey. | Investment Managers | Private Equity Investor Consultant / Advisor | |
| University of Redlands | College/University | Masters Business Admin Masters Business Admin | |
Duke University
 Duke University Other Consumer ServicesConsumer Services Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC. | College/University | Undergraduate Degree Graduate Degree | |
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| Southern Illinois University | College/University | Masters Business Admin Undergraduate Degree | |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
Origin Biosciences, Inc.
 Origin Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., Origin Biosciences, Inc. is an actively managed investment issuer focused on making equity investments in psychedelics industry-related companies to provide investors with diverse exposure to the sector. The private company is based in Palo Alto, CA. The company, led by a team of industry experts, leverages its management expertise, professional network, and due diligence process to identify and invest in leading and emerging companies focused on the emerging psychedelics sector. Michael Henderson has been the CEO of the company since 2018. | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
QED Therapeutics, Inc.
 QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The private company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | Pharmaceuticals: Major | Chief Executive Officer Chief Tech/Sci/R&D Officer | |
| METACRINE, INC. | Biotechnology | Chief Executive Officer Chief Executive Officer | |
BioVascular, Inc.
 BioVascular, Inc. Pharmaceuticals: MajorHealth Technology BioVascular, Inc. develops drugs and devices for control of intimal hyperplasia associated with vascular procedures. It is a integrated specialty cardiovascular therapeutic company, and to utilize corporate partnerships in markets that have complex marketing barriers and/or combination technologies. The company was founded by John H. Parrish and Paul F. Glidden in 2005 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Ascenta Therapeutics, Inc.
 Ascenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| Columbia Business School | College/University | Masters Business Admin Masters Business Admin | |
| Rutgers State University of New Jersey | College/University | Undergraduate Degree Undergraduate Degree | |
Venrock Associates
 Venrock Associates Investment ManagersFinance Venrock Associates is an Independent Venture Capital firm founded in 1969. The firm is headquartered in Palo Alto. | Investment Managers | Private Equity Investor Private Equity Investor | |
| VOYAGER THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director of Finance/CFO | |
Edimer Pharmaceuticals, Inc.
 Edimer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Edimer Pharmaceuticals, Inc. provides biopharmaceutical products for improving the health and quality of life of families living with XLHED. It has developed EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), which is a rare orphan disease that causes symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. The company was founded by Pascal Schneider and Olivier Gaide in 2009 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Chairman | |
| BLUEBIRD BIO, INC. | Biotechnology | Director/Board Member Chairman | |
Ren Pharmaceuticals, Inc.
 Ren Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ren Pharmaceuticals was formed in the fall of 2006 with the aim of bringing together talented and experienced people who are passionate about building a cardio-renal/renal- focused drug development company. Ren Pharmaceuticals closed a Series A financing in November 2006 with Sanderling Ventures, Venrock Associates and Amgen Ventures as investors. The company's R&D is currently located in South San Francisco, California. | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member | |
Viridian LLC
 Viridian LLC BiotechnologyHealth Technology Viridian LLC operates as a biopharmaceutical incubator. It focuses in the discovery and development of new molecular entities. The company was founded by Peter Harwin and Tomas Kiselak in 2016 and is headquartered in Philadelphia, PA. | Biotechnology | Founder Founder | |
| VIRIDIAN THERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Takeda Pharmaceuticals U.S.A., Inc.
 Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. | Pharmaceuticals: Major | Sales & Marketing President | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal General Counsel | |
| PROMETHEUS BIOSCIENCES, INC. | Biotechnology | Investor Relations Contact Chief Executive Officer | |
| Emory University | College/University | Undergraduate Degree Masters Business Admin |
Estadísticas
Internacional
| Estados Unidos | 48 |
| Australia | 2 |
| Francia | 2 |
| Suiza | 2 |
Sectorial
| Health Technology | 34 |
| Consumer Services | 15 |
| Finance | 3 |
| Commercial Services | 2 |
Operativa
| Director/Board Member | 204 |
| Corporate Officer/Principal | 114 |
| Independent Dir/Board Member | 72 |
| Chairman | 53 |
| Undergraduate Degree | 53 |
Las relaciones más conectadas
| Insiders | |
|---|---|
| Eckard Weber | 46 |
| Brian H. Dovey | 40 |
| Daniel Lynch | 32 |
| Louis C. Bock | 27 |
| Wendy Dixon | 25 |
| Jane Henderson | 24 |
| Peter Honig | 20 |
| Deborah Jorn | 20 |
| David Endicott | 18 |
| Richard Fitzgerald | 17 |
| Preston Klassen | 15 |
| Joseph Hagan | 15 |
| William Jones | 14 |
| Michael Henderson | 14 |
| Patrick Mahaffy | 13 |
- Bolsa de valores
- Insiders
- Monica Forbes
- Conexiones Empresas
